BOSSI, Paolo
 Distribuzione geografica
Continente #
NA - Nord America 10.344
EU - Europa 2.697
AS - Asia 1.017
AF - Africa 18
OC - Oceania 17
SA - Sud America 12
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.109
Nazione #
US - Stati Uniti d'America 10.308
CN - Cina 861
UA - Ucraina 841
IE - Irlanda 376
DE - Germania 345
PL - Polonia 337
IT - Italia 313
GB - Regno Unito 181
FI - Finlandia 133
SE - Svezia 86
VN - Vietnam 59
IN - India 51
CA - Canada 33
FR - Francia 30
BE - Belgio 28
AU - Australia 16
TR - Turchia 12
EG - Egitto 10
JP - Giappone 7
MY - Malesia 5
BR - Brasile 4
CH - Svizzera 4
EU - Europa 4
HK - Hong Kong 4
MK - Macedonia 4
AR - Argentina 3
IR - Iran 3
MA - Marocco 3
NL - Olanda 3
RO - Romania 3
RU - Federazione Russa 3
CZ - Repubblica Ceca 2
EC - Ecuador 2
ES - Italia 2
HR - Croazia 2
ID - Indonesia 2
KR - Corea 2
MX - Messico 2
PK - Pakistan 2
TH - Thailandia 2
TN - Tunisia 2
ZA - Sudafrica 2
CL - Cile 1
DK - Danimarca 1
FK - Isole Falkland (Malvinas) 1
IQ - Iraq 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
SG - Singapore 1
Totale 14.109
Città #
Fairfield 2.231
Ashburn 1.068
Woodbridge 898
Jacksonville 846
Seattle 827
Houston 769
Cambridge 694
Wilmington 668
Princeton 636
Chandler 416
Warsaw 337
Dublin 334
Ann Arbor 282
Beijing 188
Des Moines 157
Nanjing 156
San Diego 150
Helsinki 123
Brescia 101
London 71
Shenyang 69
Changsha 58
Dong Ket 58
Hebei 52
Jinan 52
Nanchang 52
Jiaxing 49
Tianjin 46
Menlo Park 43
Pune 40
Rome 28
Brussels 27
Ningbo 26
Norwalk 22
Milan 21
Toronto 21
Chiswick 18
Taizhou 18
Haikou 16
Hangzhou 16
San Francisco 16
New Bedfont 14
Dearborn 13
Hanover 13
Rende 13
Guangzhou 11
Cairo 10
Hounslow 10
Lanzhou 10
Prescot 10
Canberra 9
Washington 9
Zhengzhou 9
Frankfurt am Main 8
Brooklyn 7
Cazzago San Martino 7
Verona 7
Fuzhou 6
Melbourne 6
Taiyuan 6
Augusta 5
Lancaster 5
Lappeenranta 5
Leawood 5
Arezzo 4
Bonn 4
Paris 4
Petaling Jaya 4
Redwood City 4
Tokyo 4
Acton 3
Amsterdam 3
Berlin 3
Central 3
Chicago 3
Gunzenhausen 3
Kocaeli 3
Kunming 3
Los Angeles 3
Markham 3
Mountain View 3
Nagold 3
New York 3
Ozzano dell'Emilia 3
Phoenix 3
Skopje 3
Venezia 3
Victoria 3
Villa Di Tirano 3
Voghera 3
Ardabil 2
Barcelona 2
Bari 2
Boardman 2
Bucharest 2
Calcinate 2
Canton 2
Caserta 2
Cinto Caomaggiore 2
Cleveland 2
Totale 12.002
Nome #
Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements. 156
Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio 152
Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation 146
Systematic review of photobiomodulation for the managementof oral mucositis in cancer patients and clinical practice guidelines 141
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 134
Tumor biomarkers for the prediction of distant metastasis in head and neck squamous cell carcinoma 120
Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus 115
Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? 115
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 103
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 102
Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions 100
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact 98
Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus 97
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus 97
Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents 95
Investigational drugs for head and neck cancer 88
Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma 87
Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy 86
Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm 86
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 84
Hope in cancer patients: the relational domain as a crucial factor 84
The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing 84
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma 82
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 82
Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer 80
The Case Volume Issue in Head and Neck Oncology 79
Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients 78
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis 77
Primary resistances to EGFR inhibitors (EGFRi) in HPV-positive and -negative oropharyngeal squamous cell carcinoma (OSCC) 77
The role of systemic therapy in the management of sinonasal cancer: A critical review 77
Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review 76
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study 76
T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results 76
Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma 76
Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers 75
Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma 75
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 74
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma 74
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy 73
Multikinase inhibitors in thyroid cancer 73
Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development 73
TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma 72
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study 72
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma 71
Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma 71
TP53 mutations in head and neck cancer 71
Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma 70
Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (-) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) 70
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients 70
NICSO: Network Italiano Cure di Supporto in Oncologia - Italian Network for Supportive Care in Oncology 70
Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements 70
Comments on "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure" by Chan and Coll 69
Folate in head and neck squamous cell cancer chemoprevention: Purposely left out? 69
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs) 69
Pain related to cancer treatments and diagnostic procedures: a no man's land? 69
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients 68
Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options 68
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab 68
Emerging tyrosine kinase inhibitors for head and neck cancer 68
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer 67
Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor 67
Prognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers (OPCs) 67
CISPLATIN DOSE INTENSITY CORRELATES WITH OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CISPLATIN BASED CHEMORADIATION: A MULTI-INSTITUTIONAL EXPERIENCE 67
Resistance to Hedgehog inhibitor through Smoothened receptor mutation in basal cell carcinoma 67
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients 67
Receptor Tyrosine Kinase Profiles and Human Papillomavirus Status in Oropharyngeal Squamous Cell Carcinoma 67
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 67
Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience 67
Italian version of the MD Anderson Symptom Inventory-Head and Neck Module: linguistic validation 66
Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations 66
OROPHARYNGEAL SQUAMOUS CELL CARCINOMA TREATED WITH RADIOTHERAPY OR RADIOCHEMOTHERAPY: PROGNOSTIC ROLE OF TP53 AND HPV STATUS 66
Feasibility and activity of docetaxel, cisplatinum and 5-fluorouracil induction chemotherapy followed by concurrent chemo-radiotherapy (including IMRT) in locally advanced undifferentiated nasopharyngeal cancer (LANPC) 66
Induction chemotherapy within a multimodality treatment of nasal cavity and ethmoid sinus malignant epithelial tumours: report of an homogeneous series of patients 66
Radiotherapy for unresectable sinonasal cancers: Dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy 65
New insights in chemotherapy 65
Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting 65
Isolating p16-positive/HPV-negative Oropharyngeal Cancer: An Effort Worth Making 65
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis 65
Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area 65
Gastrointestinal toxicities from targeted therapies: measurement, duration and impact 65
The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer 65
How Many Therapeutic Options Are There for Recurrent or Metastatic Salivary Duct Carcinoma? 65
Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up 65
Global cancer control: responding to the growing burden, rising costs and inequalities in access 64
Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review 63
Dissecting heterogeneity and molecular mechanisms involved in paranasal sinus cancer 63
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data 63
Comprehensive meta-analysis of publicly available microarray data in head and neck cancer 63
Palifermin in Prevention of Head and Neck Cancer Radiation-Induced Mucositis: Not Yet a Definitive Word on Safety and Efficacy Profile 63
Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy 63
Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 63
Rapid-Onset Opioids for the Treatment of Breakthrough Cancer Pain: Two Cases of Drug Abuse 63
Detecting characteristics of nodal invasion in advanced squamocellular oral cavity cancer through a gene expression profile on primary tumor 62
Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis 62
Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis", by Rades et coll 61
Sinonasal Malignancies of Anterior Skull Base Histology-driven Treatment Strategies 61
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents 61
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer 60
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer 60
Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base' 60
Totale 7.716
Categoria #
all - tutte 84.327
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.327


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019920 0 0 0 0 0 0 3 6 0 14 548 349
2019/20203.642 471 116 142 434 236 386 485 392 301 383 206 90
2020/20215.199 64 476 246 999 298 729 152 519 345 723 284 364
2021/20222.337 116 253 56 283 109 212 76 202 120 195 201 514
2022/20231.551 359 89 46 113 92 464 12 103 148 30 46 49
2023/2024731 68 40 132 111 136 244 0 0 0 0 0 0
Totale 14.502